Figure 2. Mutation Testing Results Predict Response to Anti-EGFR Immunotherapy in Patients with Metastatic Colorectal Cancer

Candidate for Cetuximab or Panitumumab

Colorectal Cancer Mutation Panel
(KRAS, PIK3CA, BRAF, NRAS)
[18902]

- Mutations not detected
  - Response to anti-EGFR immunotherapy more likely

- ≥1 mutation(s) detected
  - Response to anti-EGFR immunotherapy unlikely

Test code is in brackets. This algorithm is intended as a guide for using Quest Diagnostics laboratory tests to assess the risk of Lynch syndrome. It is based on references 19-22 and is provided for informational purposes only. It is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.